To obtain the subject medicine having matrix metalloproteinase- inhibiting activities and useful as metastatic infiltration- or growth-inhibiting agents, etc., for various cancer cells, by bringing the medicine to contain a specific hydoxamic acid derivative.
The objective medicine is obtained by bringing the medicine to contain a hydroxamic acid derivative expressed by formula I [R1 is an alkyl, a cycloalkyl-methyl or an arylmethyl; R2 and R3 are a (substituted) alkyl, H or a cyclic amino group formed together with R1, R2 and bound N; R4 is an alkyl; R5 is H, a (substituted) carbamoyl or an aliphatic acyl; R6 is H, a heteroaryl-substituted alkyl, etc.], {e.g. N-[3-(S)-hydroxy-4-(N- hydroxylamino)-2-(R)-nonylsuccinyl]-L-tert-leucin-N-methyl amide}. The compound of formula I is a new compound and can be produced by using a compound of formula II (R1a expresses that a hydroxyl group in R1 is protected) as a starting material.
OKAWA NOBUYUKI
TAKEMOTO TOSHIYASU
TAMAKI KAZUHIKO
KURIHARA NOBUKAZU
SATO SUSUMU
TANZAWA KAZUHIKO
KOBAYASHI TOMOO
FUJIWARA KOSAKU
